quinta-feira, 29 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· October 22, 2026

Dow expects about $1.5B Q4 EBITDA while targeting $1.3B of self-help benefits in 2027

View original at seekingalpha.com

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • No logistics constraints from U.S. Gulf Coast; operating rates above 90%

    60% confidence
  • Net sales up 13% YoY with growth in every operating segment; operating EBITDA more than $1.5B

    60% confidence
  • Q3 sequential self-help improvement exceeded $150M; committed to ~$1.3B net benefits this year and $1.3B in 2027

    60% confidence
  • Achieving $0.07 in October and $0.05 in November PE price increases would provide ~$200M upside

    60% confidence
  • ~70% of ~4,500 role reductions implemented; substantial completion by year-end

    60% confidence
  • SARD down $130M sequentially and cost savings expected to build in SARD and COGS

    60% confidence
  • Q4 guide assumes ethane in mid- to high $0.20/gal; every $0.03/gal ethane equals ~$0.01/lb PE price

    60% confidence
  • Ethylene/PE operating rates in the low 80s; silicones a tale of two cities

    60% confidence
  • Persistently high energy costs challenge European economics; Rhine record low water disrupted logistics

    60% confidence
  • ~$14B liquidity and no substantive debt maturities until 2029

    60% confidence
  • Q4 seasonality largely offset by >$100M lower turnaround spending and ~$100M sequential self-help uplift

    60% confidence
  • Global PE integrated margins expected to improve ~$0.02/lb vs Q3

    60% confidence
  • Q3 free cash flow $1.1B; working capital sequential improvement ~$1.3B; 2027 cash conversion 70% to 80%

    60% confidence
  • MDI markets remain soft; expects move back to a longer market in Q4

    60% confidence
  • Sadara financial boundary established; equity loss recognition suspended; funding commitment limited to ~$1.3B; engaged with Aramco

    60% confidence
  • Constrained JVs limited volumes; P&SP excluding that grew 2%

    60% confidence
  • Path2Zero Alberta ~45% complete; first phase end of 2029, second phase 2030; open to partnering options

    60% confidence
  • Q4 EBITDA expected at approximately $1.5B

    60% confidence
  • Transform to Outperform ahead of schedule; on track for ~$700M growth and productivity improvements this year

    60% confidence
  • Won't call a 2027 EBITDA number; $1.3B tailwinds = $1.2B Transform to Outperform + ~$100M asset actions

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,994
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,994 factos verificados com a fonte5,503 documentos-fonte arquivados
Consulte estes dados → isubstrate.com